SoftOx Solutions AS (SOFTX) - Total Liabilities

Latest as of December 2025: Nkr10.98 Million NOK ≈ $1.16 Million USD

Based on the latest financial reports, SoftOx Solutions AS (SOFTX) has total liabilities worth Nkr10.98 Million NOK (≈ $1.16 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can SoftOx Solutions AS fund operations to measure how many days the company can operate on defensive assets alone.

SoftOx Solutions AS - Total Liabilities Trend (2016–2025)

This chart illustrates how SoftOx Solutions AS's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of SoftOx Solutions AS to evaluate the company's liquid asset resilience ratio.

SoftOx Solutions AS Competitors by Total Liabilities

The table below lists competitors of SoftOx Solutions AS ranked by their total liabilities.

Company Country Total Liabilities
True North Copper Ltd
AU:TNC
Australia AU$23.71 Million
DocGo Inc
NASDAQ:DCGO
USA $98.02 Million
Haverty Furniture Companies Inc
NYSE:HVT-A
USA $345.68 Million
Kristal Kola ve Mesrubat Sanayi Ticaret AS
IS:KRSTL
Turkey TL1.03 Billion
Imas Makina Sanayi AS
IS:IMASM
Turkey TL1.62 Billion
Tactical Resources Corp. Common Shares
NASDAQ:TREO
USA $9.29 Million
Ditas Dogan Yedek Parca Imalat ve Teknik AS
IS:DITAS
Turkey TL2.35 Billion
Samwha Elec
KO:011230
Korea ₩56.82 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down SoftOx Solutions AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SoftOx Solutions AS (SOFTX) total assets.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.80 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.48 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.32 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SoftOx Solutions AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SoftOx Solutions AS (2016–2025)

The table below shows the annual total liabilities of SoftOx Solutions AS from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 Nkr10.98 Million
≈ $1.16 Million
-57.71%
2024-12-31 Nkr25.96 Million
≈ $2.73 Million
-72.64%
2023-12-31 Nkr94.87 Million
≈ $9.98 Million
+53.45%
2022-12-31 Nkr61.83 Million
≈ $6.51 Million
+237.34%
2021-12-31 Nkr18.33 Million
≈ $1.93 Million
+65.23%
2020-12-31 Nkr11.09 Million
≈ $1.17 Million
-40.03%
2019-12-31 Nkr18.50 Million
≈ $1.95 Million
+105.86%
2018-12-31 Nkr8.98 Million
≈ $945.45K
+114.38%
2017-12-31 Nkr4.19 Million
≈ $441.01K
-34.30%
2016-12-31 Nkr6.38 Million
≈ $671.23K
--

About SoftOx Solutions AS

OL:SOFTX Norway Biotechnology
Market Cap
$33.36 Million
Nkr317.07 Million NOK
Market Cap Rank
#23447 Global
#216 in Norway
Share Price
Nkr0.12
Change (1 day)
-5.10%
52-Week Range
Nkr0.05 - Nkr0.16
All Time High
Nkr112.00
About

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that anti-infective therapy for airway infections in Norway. The company develops SIS-03, a lead clinical program that is in phase 2a to treatment of chronic airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, yeast, spores, and fungi. SoftOx So… Read more